Balancing technology and patient care can enhance communication and data collection, improving adherence and outcomes in specialty pharmacy, said Kathi Henson, MBA, of Orsini.
Matching the right technology to the right patient can improve communication and data collection, said Kathi Henson, MBA, senior vice president of patient services, nursing, and quality at Orsini. Collecting data on patient adherence can then be used to intervene when necessary to improve outcomes.
Transcript edited for clarity; captions were auto-generated.
Transcript
How do you balance the use of technology with maintaining a patient-centered approach in specialty pharmacy care?
The key word is balance, right? It can't be all technology and all people; those things just don't make sense. But by balancing each it really helps to direct the resources to the right areas. Technology also enables us to communicate with patients in a way that they prefer. Right now, if you call me, I'm not likely going to pick up the phone. I'm very busy. But if I can use tech, things like texting or other means—email—of electronic communication, you're much more likely to get an answer. We've been able to start to use that to create surveys in different ways, to collect data from patients as well, and then supplement that with actual people resources.
What key metrics should specialty pharmacies track to measure the impact of data-driven interventions on patient adherence and outcomes?
The typical metrics we use are things called MPRs, medication possession ratio, and PDC [proportion of days covered]. MPR and PDC are really 2 measures that are pretty much an industry standard, and I think it's important to use those to assess how well the patient is staying adherent. But it also allows us to see where there might be potentially issues, or where those fall-offs might occur over time. Your patient could be doing really well at the beginning, and maybe after 5 or 6 months they start to fall off, and maybe that's where we need to make an intervention. Just some things like that. A lot of pharmacies use those, but I do think they're important. [They’re] definitely important measures to monitor specifically over time.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS
June 2nd 2025Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.
Read More
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More
Multicancer Detection Assays Remain Largely Elusive for Early-Stage Disease Detection
June 1st 2025Multicancer early detection tests are revolutionizing cancer screening by using liquid biopsies to screen for multiple cancers from a single blood sample, enhancing patient outcomes by identifying cancers earlier.
Read More